Akari Therapeutics, Plc

Akari Therapeutics, Plc - Enterprise Valueverified

AKTX

Price:

$7.5

Market Cap:

$8.58M

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bisp...[Read more]

Industry

Biotechnology

IPO Date

2014-01-06

Stock Exchange

NASDAQ

Ticker

AKTX

The Enterprise Value as of August 2026 (TTM) for Akari Therapeutics, Plc (AKTX) is 6.55M

According to Akari Therapeutics, Plc’s latest financial reports and current stock price. The company's current Enterprise Value is 6.55M. This represents a change of -517.88% compared to the average of -1567045.88 of the last 4 quarters.

Akari Therapeutics, Plc (AKTX) Historical Enterprise Value (quarterly & annually)

How has AKTX Enterprise Value performed in the past?

The mean historical Enterprise Value of Akari Therapeutics, Plc over the last ten years is -11142518.79. The current 6.55M Enterprise Value has changed -5976.95% with respect to the historical average. Over the past ten years (40 quarters), AKTX's Enterprise Value was at its highest in in the December 2024 quarter at 1.13M. The Enterprise Value was at its lowest in in the December 2016 quarter at -32932988.00.

Quarterly (TTM)
Annual

Average

-11142518.79

Median

-6779055.00

Minimum

-32823164.00

Maximum

952.43K

Akari Therapeutics, Plc (AKTX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Akari Therapeutics, Plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 163.65%

Maximum Annual Enterprise Value = 952.43K

Minimum Annual Increase = -541.58%

Minimum Annual Enterprise Value = -32823164.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2025-4205777.14-541.58%
2024952.43K-126.91%
2023-3539614.40-72.05%
2022-12663252.0056.85%
2021-8073670.00-39.86%
2020-13423817.00163.65%
2019-5091500.00-7.16%
2018-5484440.00-79.74%
2017-27072387.00-17.52%
2016-32823164.00-50.60%

Akari Therapeutics, Plc (AKTX) Average Enterprise Value

How has AKTX Enterprise Value performed in the past?

The current Enterprise Value of Akari Therapeutics, Plc (AKTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-2264319.31

5-year avg

-5505975.99

10-year avg

-11142518.79

Akari Therapeutics, Plc (AKTX) Enterprise Value vs. Peers

How is AKTX’s Enterprise Value compared to its peers?

Akari Therapeutics, Plc’s Enterprise Value is greater than Purple Biotech Ltd. (-3648009.04), greater than Syros Pharmaceuticals, Inc. (-77448317.00), less than CDT Equity Inc. (972.32M), greater than Longevity Health Holdings Inc. (408.88K), greater than Revelation Biosciences, Inc. (-8859688.00), greater than Dermata Therapeutics, Inc. (-6147860.00), less than MSP Recovery, Inc. (759.66M), greater than Psyence Biomedical Ltd. (-7382190.00), greater than Vincerx Pharma, Inc. (-4920525.00), greater than Virpax Pharmaceuticals, Inc. (-1512933.00),

Build a custom stock screener for Akari Therapeutics, Plc (AKTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Akari Therapeutics, Plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Akari Therapeutics, Plc (AKTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Akari Therapeutics, Plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Akari Therapeutics, Plc's Enterprise Value?

What is the highest Enterprise Value for Akari Therapeutics, Plc (AKTX)?

What is the 3-year average Enterprise Value for Akari Therapeutics, Plc (AKTX)?

What is the 5-year average Enterprise Value for Akari Therapeutics, Plc (AKTX)?

How does the current Enterprise Value for Akari Therapeutics, Plc (AKTX) compare to its historical average?